IDO1 and neoplasm: IDO-mediated resistance to ipilimumab [14] and endogenous anti-tumor immune activity [16] have sparked interest in development of new IDO inhibitors for potential combination with other immunotherapy drugs in treatment of cancer (NCT01792050).